ELEVATED SERUM PENTRAXIN-3 LEVELS IS POSITIVELY CORRELATED TO DISEASE SEVERITY AND COAGULOPATHY IN COVID-19 PATIENTS
Main Article Content
Keywords
Coronavirus disease 2019, Pentraxin-3, D-dimer, Coagulopathy, Disease Severity
Abstract
Abstract
BACKGROUND Coronavirus disease 2019 (COVID-19) is highly contagious and deadly and is associated with coagulopathy. Pentraxin-3(PTX3) participates in innate resistance to infections and plays a role in thrombogenesis.
PURPOSE The present study aimed to investigate the role of PTX3 in coagulopathy in patients with COVID-19.
METHODS A retrospective study including thirty-nine COVID-19 patients enrolled in Hunan, China were performed. The patients were classified into the D-dimer_L (D-dimer?1mg/L) and D-dimer_H (D-dimer?1mg/L) groups basing on the plasma D-dimer levels on admission. Serum PTX3 levels were detected by enzyme-linked immunosorbent assays and compared between those two groups, and then linear regression models were applied to analyze the association between PTX3 and D-dimer.
RESULTS Our results showed that serum PTX3 levels (median values, 10.21 vs 3.36, P < 0.001), chest computerized tomography scores (median values, 10.0 vs 9.0, P < 0.05), and length of stay (16.0±4.2 vs 10.7±3.6, P = 0.001) in the D-dimer_H group were significantly higher than that in D-dimer_L group. The coefficient of determination for PTX3 was 0.651 (P < 0.001) in the D-dimer_H group.
CONCLUSION Serum level of PTX3 was positively correlated with disease severity and coagulopathy. Detection of serum PTX3 level could assist to identify severer patients on admission and may be a potential therapeutic target for coagulopathy in patients with COVID-19.
Downloads
Abstract 1006
PDF Downloads 351
HTML Downloads 141
References
2. Johns Hopkins University. Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html. (Accessed 1 Sep 2020).
3. Porte R, Davoudian S, Asgari F, Parente R, Mantovani A, Garlanda C, Bottazzi B. The Long Pentraxin PTX3 as a Humoral Innate Immunity Functional Player and Biomarker of Infections and Sepsis. Front Immunol. 2019 Apr 12;10:794. doi: 10.3389/fimmu.2019.00794.
4. Zlibut A, Bocsan IC, Agoston-Coldea L. Pentraxin-3 and endothelial dysfunction. Adv Clin Chem. 2019;91:163-179. doi: 10.1016/bs.acc.2019.03.005.
5. Yang H, Zhang J, Huan Y, Xu Y, Guo R. Pentraxin-3 Levels Relate to the Wells Score and Prognosis in Patients with Acute Pulmonary Embolism. Dis Markers. 2019 Mar 12;2019:2324515. doi: 10.1155/2019/2324515.
6. Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res. 2020 Jun;190:62. doi: 10.1016/j.thromres.2020.04.014.
7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3.
8.National Health Commission of the People’s Republic of China home page. http://www.nhc.gov.cn. (published 3 March 2020).
9. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, Zhao L, Fan H, Luo S, Hu D. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020 Mar 31;e3319. doi: 10.1002/dmrr.3319.
10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
11. Bottazzi B, Inforzato A, Messa M, Barbagallo M, Magrini E, Garlanda C, Mantovani A. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol. 2016 Jun;64(6):1416-27. doi: 10.1016/j.jhep.2016.02.029.
12. Garlanda C, Bottazzi B, Magrini E, Inforzato A, Mantovani A. PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and Cancer. Physiol Rev. 2018 Apr 1;98(2):623-639. doi: 10.1152/physrev.00016.2017.
13. Reading PC, Bozza S, Gilbertson B, Tate M, Moretti S, Job ER, Crouch EC, Brooks AG, Brown LE, Bottazzi B, Romani L, Mantovani A. Antiviral activity of the long chain pentraxin PTX3 against influenza viruses. J Immunol. 2008 Mar 1;180(5):3391-8. doi: 10.4049/jimmunol.180.5.3391.
14. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA. Hematological findings and complications of COVID-19. Am J Hematol. 2020 Jul;95(7):834-847. doi: 10.1002/ajh.25829.
15. Perea L, Coll M, Sanjurjo L, Blaya D, Taghdouini AE, Rodrigo-Torres D, Altamirano J, Graupera I, Aguilar-Bravo B, Llopis M, Vallverdú J, Caballeria J, van Grunsven LA, Sarrias MR, Ginès P, Sancho-Bru P. Pentraxin-3 modulates lipopolysaccharide-induced inflammatory response and attenuates liver injury. Hepatology. 2017 Sep;66(3):953-968. doi: 10.1002/hep.29215.
16. Kao SJ, Yang HW, Tsao SM, Cheng CW, Bien MY, Yu MC, Bai KJ, Yang SF, Chien MH. Plasma long pentraxin 3 (PTX3) concentration is a novel marker of disease activity in patients with community-acquired pneumonia. Clin Chem Lab Med. 2013 Apr;51(4):907-13. doi: 10.1515/cclm-2012-0459.
17. Luo Q, He X, Ning P, Zheng Y, Yang D, Xu Y, Shang Y, Gao Z. Admission Pentraxin-3 Level Predicts Severity of Community-Acquired Pneumonia Independently of Etiology. Proteomics Clin Appl. 2019 Jul;13(4):e1800117. doi: 10.1002/prca.201800117.
18. Han B, Ma X, Zhang J, Zhang Y, Bai X, Hwang DM, Keshavjee S, Levy GA, McGilvray I, Liu M. Protective effects of long pentraxin PTX3 on lung injury in a severe acute respiratory syndrome model in mice. Lab Invest. 2012 Sep;92(9):1285-96. doi: 10.1038/labinvest.2012.92.
19. Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, Atif SM, Hariprasad G, Hasan GM, Hassan MI. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165878.
20. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schröder AS, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S, Becker H, Bredereke-Wiedling H, de Weerth A, Paschen HR, Sheikhzadeh-Eggers S, Stang A, Schmiedel S, Bokemeyer C, Addo MM, Aepfelbacher M, Püschel K, Kluge S. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. Ann Intern Med. 2020 Aug 18;173(4):268-277. doi: 10.7326/M20-2003.
21. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, Aaron JG, Claassen J, Rabbani LE, Hastie J, Hochman BR, Salazar-Schicchi J, Yip NH, Brodie D, O'Donnell MR. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020 Jun 6;395(10239):1763-1770. doi: 10.1016/S0140-6736(20)31189-2.
22. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5.
23. Gresele P, Momi S, Guglielmini G. Nitric oxide-enhancing or -releasing agents as antithrombotic drugs. Biochem Pharmacol. 2019 Aug;166:300-312. doi: 10.1016/j.bcp.2019.05.030.
24. Incalza MA, D'Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018 Jan;100:1-19. doi: 10.1016/j.vph.2017.05.005.
25. Lam FW, Da Q, Guillory B, Cruz MA. Recombinant Human Vimentin Binds to P-Selectin and Blocks Neutrophil Capture and Rolling on Platelets and Endothelium. J Immunol. 2018 Mar 1;200(5):1718-1726. doi: 10.4049/jimmunol.1700784.
26. McEver RP. Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc Res. 2015 Aug 1;107(3):331-9. doi: 10.1093/cvr/cvv154.
27. Carrizzo A, Lenzi P, Procaccini C, Damato A, Biagioni F, Ambrosio M, Amodio G, Remondelli P, Del Giudice C, Izzo R, Malovini A, Formisano L, Gigantino V, Madonna M, Puca AA, Trimarco B, Matarese G, Fornai F, Vecchione C. Pentraxin 3 Induces Vascular Endothelial Dysfunction Through a P-selectin/Matrix Metalloproteinase-1 Pathway. Circulation. 2015 Apr 28;131(17):1495-505; discussion 1505. doi: 10.1161/CIRCULATIONAHA.114.014822.
28. Napoleone E, Di Santo A, Bastone A, Peri G, Mantovani A, de Gaetano G, Donati MB, Lorenzet R. Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation. Arterioscler Thromb Vasc Biol. 2002 May 1;22(5):782-7. doi: 10.1161/01.atv.0000012282.39306.64.
29. Napoleone E, di Santo A, Peri G, Mantovani A, de Gaetano G, Donati MB, Lorenzet R. The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation. J Leukoc Biol. 2004 Jul;76(1):203-9. doi: 10.1189/jlb.1003528.
30. Kasuda S, Sakurai Y, Tatsumi K, Takeda T, Kudo R, Yuui K, Hatake K. Enhancement of Tissue Factor Expression in Monocyte-Derived Dendritic Cells by Pentraxin 3 and Its Modulation by C1 Esterase Inhibitor. Int Arch Allergy Immunol. 2019;179(2):158-164. doi: 10.1159/000496744.
31. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J . Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020 Jun;220:1-13. doi: 10.1016/j.trsl.2020.04.007.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.